Results 11 to 20 of about 31,941 (191)

Prevalence of multidrug-resistant tuberculosis in East Africa: A systematic review and meta-analysis.

PLoS ONE, 2022
BackgroundThe rate of multidrug-resistant tuberculosis is increasing at an alarming rate throughout the world. It is becoming an emerging public health problem in East Africa.
Kindu Alem Molla, Melese Abate Reta, Yonas Yimam Ayene   +2 more
doaj   +1 more source

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study. [PDF]

PLoS ONE, 2015
Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases.
Helen R Stagg, James Brown, Elmira Ibraim, Vija Riekstiņa, Piret Viiklepp, Andra Cīrule, Horia Cocei, Manfred Danilovitš, Gunta Dravniece, Charlotte Jackson, Peter J White   +10 more
doaj   +1 more source

Multidrug-resistant tuberculosis today [PDF]

Bulletin of the World Health Organization, 2012
The World Health Organization (WHO) and its partners have long conducted efforts to improve tuberculosis (TB) case surveillance and programme monitoring and evaluation. WHO’s 2011 report on global TB control1 provided the most reliable information ever generated on the burden of disease and death caused by TB and multidrug-resistant TB (i.e.
Matteelli, A., Centis, R., D'Ambrosio, L., Migliori, G. B.   +3 more
openaire   +5 more sources

Trends in multidrug-resistant tuberculosis [PDF]

Journal of Venomous Animals and Toxins including Tropical Diseases, 2008
Multidrug-resistant tuberculosis (MDR-TB) is an increasing global problem. The extent and burden of MDR-TB varies significantly from country to country and region to region. Globally, about three per cent of all newly diagnosed patients have MDR-TB and the proportion is higher in patients who had previously received anti-tuberculosis (anti-TB ...
Dias-Baptista, I. M. F., Usó, S. M. R. S., Marcondes-Machado, J.   +2 more
openaire   +5 more sources

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Periodontology 2000, EarlyView., 2023
Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera, Arie Jan van Winkelhoff, Paula Matesanz, Katalina Lauwens, Wim Teughels   +4 more
wiley   +1 more source

SHORT-TERM CHEMOTHERAPY REGIMEN OF MULTIDRUG-RESISTANT TUBERCULOSIS IN THE KYRGYZ REPUBLIC

Паёми Сино, 2018
Objective: To study the clinical course of tuberculosis (TB) with multiple drug resistance (MDR) in the treatment of short-term courses recommended by the WHO.
E.V. ZHDANOVA, G.K. TURDUMAMBETOVA
doaj   +1 more source

An update on multidrug-resistant tuberculosis [PDF]

Clinical Medicine, 2019
Of the 10 million incident cases of tuberculosis (TB) globally in 2017, around 558,000 cases were rifampicin-resistant of which 82% were multidrug-resistant (MDR) TB. In England, 5,102 cases were recorded of which 55 cases (1.8%) were MDR-TB. MDR-TB cases have worse outcomes and are a serious public health issue.Polymerase chain reaction (PCR) tests ...
Onn Min Kon, Onn Min Kon, Giovanni Satta, Mirae Park   +3 more
openaire   +5 more sources

Saarvienin A—A Novel Glycopeptide with Potent Activity against Drug‐Resistant Bacteria

Angewandte Chemie, EarlyView.
A structurally distinct glycopeptide, saarvienin A, represents a new family of glycopeptide antibiotics consisting of five sugar/aminosugar units connected to a halogenated peptide core. Saarvienin A overcomes vancomycin resistance and shows strong activity against drug‐resistant Gram‐positive bacteria, in particular, high‐priority pathogens such as ...
Amninder Kaur, Jaime Felipe Guerrero‐Garzón, Sari Rasheed, Martin Zehl, Franziska Fries, Bernd Morgenstern, Sergey B. Zotchev, Rolf Müller   +7 more
wiley   +2 more sources

Management of patients with multidrug-resistant tuberculosis [PDF]

The International Journal of Tuberculosis and Lung Disease, 2019
The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today.
Lange, C., Aarnoutse, R., Alffenaar, J., Bothamley, G., Brinkmann, F., Costa, J., Chesov, D., van Crevel, R., Dedicoat, M., Dominguez, J., Duarte, R., Grobbel, H., Günther, G., Heyckendorf, J., Kay, A., Kirakosyan, O., Kirk, O., Koczulla, R., Guglielmetti, Lorenzo, Kudriashov, G., Kuksa, L., van Leth, F., Magis-Escurra, C., Mandalakas, A., Molina-Moya, B., Peloquin, C., Reimann, M., Rumetshofer, R., Schaaf, H., Schön, T., Tiberi, S., Valda, J., Yablonskii, P., Dheda, K.   +33 more
openaire   +9 more sources

Multidrug-Resistant Tuberculosis

Chest, 2006
Multidrug-resistant tuberculosis (MDR-TB) caused by Mycobacterium tuberculosis resistant to both isoniazid and rifampicin with or without resistance to other drugs is among the most worrisome elements of the pandemic of antibiotic resistance. Globally, about three per cent of all newly diagnosed patients have MDR-TB.
Alladi Mohan, Surendra K. Sharma
openaire   +3 more sources